4564 Stock Overview
Engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
OncoTherapy Science, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥32.00 |
| 52 Week High | JP¥64.00 |
| 52 Week Low | JP¥15.00 |
| Beta | 0.47 |
| 11 Month Change | 3.23% |
| 3 Month Change | -37.25% |
| 1 Year Change | 23.08% |
| 33 Year Change | -58.44% |
| 5 Year Change | -64.84% |
| Change since IPO | -97.60% |
Recent News & Updates
Shareholder Returns
| 4564 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 6.7% | -6.1% | -0.7% |
| 1Y | 23.1% | 16.5% | 10.8% |
Return vs Industry: 4564 exceeded the JP Biotechs industry which returned 16.5% over the past year.
Return vs Market: 4564 exceeded the JP Market which returned 10.8% over the past year.
Price Volatility
| 4564 volatility | |
|---|---|
| 4564 Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.6% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4564's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4564's weekly volatility has decreased from 18% to 10% over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 54 | Junichi Shimada | www.oncotherapy.co.jp |
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer.
OncoTherapy Science, Inc. Fundamentals Summary
| 4564 fundamental statistics | |
|---|---|
| Market cap | JP¥8.69b |
| Earnings (TTM) | -JP¥1.12b |
| Revenue (TTM) | JP¥479.00m |
18.1x
P/S Ratio-7.7x
P/E RatioIs 4564 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4564 income statement (TTM) | |
|---|---|
| Revenue | JP¥479.00m |
| Cost of Revenue | JP¥1.17b |
| Gross Profit | -JP¥687.00m |
| Other Expenses | JP¥436.00m |
| Earnings | -JP¥1.12b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.13 |
| Gross Margin | -143.42% |
| Net Profit Margin | -234.45% |
| Debt/Equity Ratio | 0% |
How did 4564 perform over the long term?
See historical performance and comparison